Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Finding aid

Document registry — page 8

Every document the Institute has published, 1,621 in total, with its identifier, type, certainty rating and review date.

Documents

1,621 documents · page 8 of 41
  • CEI-GT-139Defined term2026-q3

    The counter-ion most commonly introduced by reverse-phase purification with trifluoroacetic acid. Quantified by ion chromatography or fluorine nuclear magnetic…

    30 Jul 2026
  • CEI-GT-140Defined term2026-q3

    The reference method for water content, based on the stoichiometric reaction of water with iodine and sulfur dioxide. The only water determination the Institute accepts…

    30 Jul 2026
  • CEI-GT-141Defined term2026-q3

    The mass fraction of a lyophilisate that is water. Substantial for a hygroscopic peptide and a direct subtraction from delivered peptide mass.

    30 Jul 2026
  • CEI-GT-142Defined term2026-q3

    Determination of mass-to-charge ratio, used to confirm identity. For a peptide, deconvolution of the multiply charged envelope should return an average mass within a…

    30 Jul 2026
  • CEI-GT-143Defined term2026-q3

    The mass calculated using the most abundant isotope of each element. Requires high resolving power to determine for a peptide of several kilodaltons, and is not…

    30 Jul 2026
  • CEI-GT-144Defined term2026-q3

    The mass calculated using isotope-averaged atomic weights, and the value returned by deconvolution of an electrospray charge envelope at moderate resolution.

    30 Jul 2026
  • CEI-GT-145Defined term2026-q3

    A second analytical method resting on a different physical principle from the first. Identity confirmed by two orthogonal methods is materially stronger than identity…

    30 Jul 2026
  • CEI-GT-146Defined term2026-q3

    Confirmation that the material is the substance claimed. Retention-time correspondence alone is weak evidence of identity; mass-spectrometric confirmation of the…

    30 Jul 2026
  • CEI-GT-147Defined term2026-q3

    Enzymatic digestion followed by chromatographic and mass-spectrometric analysis of the resulting fragments, used to confirm sequence. Rarely performed on research-supply…

    30 Jul 2026
  • CEI-GT-148Defined term2026-q3

    Impurities structurally related to the target peptide, arising from synthesis or degradation. Reported by name and retention time on a complete certificate and as a…

    30 Jul 2026
  • CEI-GT-149Defined term2026-q3

    An impurity lacking one or more residues, arising from incomplete coupling during synthesis. Often close-eluting and detectable only by mass spectrometry.

    30 Jul 2026
  • CEI-GT-150Defined term2026-q3

    Conversion of asparagine or glutamine to the corresponding acid, adding one dalton and altering charge. A principal storage-related degradation route for peptides in…

    30 Jul 2026
  • CEI-GT-151Defined term2026-q3

    Conversion of aspartate to isoaspartate through a succinimide intermediate, producing a species of identical mass and different retention. Undetectable by mass alone.

    30 Jul 2026
  • CEI-GT-152Defined term2026-q3

    Addition of oxygen to methionine, tryptophan or cysteine, adding sixteen daltons. Accelerated by peroxide, light and metal ions.

    30 Jul 2026
  • CEI-GT-153Defined term2026-q3

    Association of peptide molecules into higher-order species, driven by agitation, freeze–thaw cycling and proximity to the isoelectric point. Not detected by a…

    30 Jul 2026
  • CEI-GT-154Defined term2026-q3

    Separation by hydrodynamic radius, the standard method for aggregate determination. Reported on no certificate in the Institute’s sampled set.

    30 Jul 2026
  • CEI-GT-155Defined term2026-q3

    Lipopolysaccharide from Gram-negative bacterial cell walls, pyrogenic on parenteral administration. Determined by a lysate-based or recombinant assay against a dose- and…

    30 Jul 2026
  • CEI-GT-156Defined term2026-q3

    The absence of viable microorganisms, demonstrated by a compendial test on the finished presentation. Distinct from endotoxin content, which persists after sterilisation.

    30 Jul 2026
  • CEI-GT-157Defined term2026-q3

    The proportion of residues in the intended stereochemical configuration. Racemisation during synthesis produces species of identical mass and identical reverse-phase…

    30 Jul 2026
  • CEI-GT-158Defined term2026-q3

    The lowest concentration at which a determination can be made with stated precision and accuracy. An impurity below the limit is not absent; it is unquantified.

    30 Jul 2026
  • CEI-GT-159Defined term2026-q3

    The lowest concentration at which the presence of a species can be distinguished from noise. Lower than the limit of quantitation and not a basis for a numerical result.

    30 Jul 2026
  • CEI-GT-160Defined term2026-q3

    A characterised material with an assigned content value against which a determination is made. A result obtained without a named standard reports an area percentage…

    30 Jul 2026
  • CEI-GT-161Defined term2026-q3

    Repeated freezing and thawing of a solution. Concentrates solutes in the shrinking liquid fraction, drives pH excursion as buffer components crystallise differentially…

    30 Jul 2026
  • CEI-GT-162Defined term2026-q3

    The time a reconstituted preparation may be stored and used, supported by stability-indicating data on that presentation. The Institute publishes no in-use claim for any…

    30 Jul 2026
  • CEI-GT-163Defined term2026-q3

    Loss of peptide to container and syringe surfaces, material at low concentration in the absence of a surfactant. A source of content loss that no certificate reports.

    30 Jul 2026
  • CEI-GT-164Defined term2026-q3

    The document accompanying a batch, reporting the determinations made and the results obtained. Its value depends entirely on which fields it carries and whether the…

    30 Jul 2026
  • CEI-GT-165Defined term2026-q3

    The Institute’s specification of the fields a certificate must carry for a purity or content claim to be interpretable. Fields are classified as critical or recommended…

    30 Jul 2026
  • CEI-GT-166Defined term2026-q3

    The linkage between a certificate and the specific batch supplied, by batch identifier and date. A certificate that cannot be linked to the material in hand is a…

    30 Jul 2026
  • CEI-GT-167Defined term2026-q3

    Analysis performed by a laboratory independent of the supplier. Stronger evidence than a supplier-issued certificate, and weaker than analysis of an independently…

    30 Jul 2026
  • CEI-GT-168Defined term2026-q3

    The record of where an analysed sample came from and who selected it. A supplier-selected sample and an independently purchased one are different classes of evidence and…

    30 Jul 2026
  • CEI-GT-169Defined term2026-q3

    In an Institute supplier dossier, a determination supported by documentation the Institute has examined. Verification is of the documentation and never of the product…

    30 Jul 2026
  • CEI-GT-170Defined term2026-q3

    In an Institute supplier dossier, a claim for which the Institute has looked for supporting documentation and not found it. Distinct from not assessed.

    30 Jul 2026
  • CEI-GT-171Defined term2026-q3

    In an Institute supplier dossier, an attribute the Institute did not examine. Carries no implication about the attribute and is recorded so that a reader can distinguish…

    30 Jul 2026
  • CEI-GT-172Defined term2026-q3

    A supply designation indicating that material is not manufactured under a marketing authorisation and is not approved for human or veterinary use in any jurisdiction. A…

    30 Jul 2026
  • CEI-GT-173Defined term2026-q3

    A regulated system of controls over manufacture, in which a claim of compliance is meaningful only where an inspecting authority is named. An unverified compliance claim…

    30 Jul 2026
  • CEI-GT-174Defined term2026-q3

    The international standard for the competence of testing laboratories. Accreditation is granted for named tests within a defined scope; a laboratory accredited for one…

    30 Jul 2026
  • CEI-GT-175Defined term2026-q3

    Permission from a competent authority to place a medicine on the market for a stated indication. Specific to product, indication, presentation and jurisdiction.

    30 Jul 2026
  • CEI-GT-176Defined term2026-q3

    Holding no marketing authorisation for the use in question. A compound may be approved in one indication and unapproved in another, and approved in one jurisdiction and…

    30 Jul 2026
  • CEI-GT-177Defined term2026-q3

    Use of an authorised product outside the terms of its authorisation. A regulated product used outside its licence, and distinct from an unapproved product, though the…

    30 Jul 2026
  • CEI-GT-178Defined term2026-q3

    The most prominent warning a competent authority can require in product information. Signals regulatory concern; does not itself establish that the risk is realised in…

    30 Jul 2026

page 8 of 41

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.